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ABSTRACT
Neuroblastoma, a paediatric malignant tumor, is initially sensitive to etoposide, 
a drug to which many patients develop chemoresistance. In order to investigate the 
molecular mechanisms responsible for etoposide chemoresistance, HTLA-230, a human 
MYCN-amplified neuroblastoma cell line, was chronically treated with etoposide at a 
concentration that in vitro mimics the clinically-used dose. The selected cells (HTLA-
Chr) acquire multi-drug resistance (MDR), becoming less sensitive than parental 
cells to high doses of etoposide or doxorubicin. MDR is due to several mechanisms 
that together contribute to maintaining non-toxic levels of H2O2. In fact, HTLA-Chr 
cells, while having an efficient aerobic metabolism, are also characterized by an 
up-regulation of catalase activity and higher levels of reduced glutathione (GSH), 
a thiol antioxidant compound. The combination of such mechanisms contributes to 
prevent membrane lipoperoxidation and cell death. Treatment of HTLA-Chr cells with 
L-Buthionine-sulfoximine, an inhibitor of GSH biosynthesis, markedly reduces their 
tumorigenic potential that is instead enhanced by the exposure to N-Acetylcysteine, 
able to promote GSH synthesis.
Collectively, these results demonstrate that GSH and GSH-related responses play 
a crucial role in the acquisition of MDR and suggest that GSH level monitoring is an 
efficient strategy to early identify the onset of drug resistance and to control the 
patient’s response to therapy.
INTRODUCTION
Neuroblastoma is a childhood solid tumor 
originating from progenitor cells of the sympathetic 
nervous system and accounts for 8-10% of all childhood 
cancers and 15% of deaths from pediatric cancer [1–3]. 
It is characterized by a plethora of biological behaviors 
which range from tumors which regress or differentiate 
spontaneously into ganglioneuromas to highly aggressive 
forms which are frequently fatal. High-risk (HR) 
neuroblastoma is characterized by metastatic disease and/
or amplification of the MYCN proto-oncogene that is a 
biomarker still used today to stratify risk [2–6].
Current treatment for HR patients includes intensive 
and toxic chemotherapy followed by surgical resection, 
myeloablation and autologous stem cell rescue, radiation, 
and intensive immunotherapy [7–9]. Although most HR 
patients initially respond to chemotherapy, the majority of 
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them relapse and succumb to the therapy-resistant disease 
[7–9]. Standard chemotherapy for HR patients combines 
several compounds and among them etoposide is widely 
used [10–12]. Etoposide has anti-tumor effects both as a 
single agent and as part of multi-drug regimens, but its 
side-effects [13, 14] and chemoresistance limit its clinical 
success [15].
Chemoresistance is a multifactorial phenomenon 
and the availability of antioxidants is recognized as one 
of the critical factors able to provide cancer cells with 
resistance to anticancer therapies.
For this reason, several anticancer drugs produce 
high levels of reactive oxygen species (ROS), which 
cause cell death. Unfortunately, cancer cells adapt by 
up-regulating antioxidant proteins and ROS scavenging 
systems to keep ROS levels under the cytotoxic limit. 
Since several studies have reported that chemoresistant 
phenotypes of cancer cells display high levels of 
glutathione (GSH) [16], the intracellular oxidative status 
has been hypothesized to being a marker of drug efficacy 
in cancer patients [17].
In this context, the aims of the present study are 
firstly, to select for a MYCN-amplified neuroblastoma 
cell line resistant to etoposide, in order to investigate the 
mechanisms of chemoresistance and secondly, to clarify 
the role of GSH and GSH-related events in the redox 
homeostasis, potentially responsible for chemoresistance.
RESULTS
Chronically-etoposide-treated neuroblastoma 
cells are less proliferating and tumorigenic 
than the parental ones and they don’t undergo 
apoptosis after etoposide exposure
In order to select an etoposide-resistant cell line, 
HTLA-230, MYCN-amplified human neuroblastoma cells, 
isolated from a stage IV patient, were treated for 6 months 
with increasing concentrations of etoposide (1 nM-1.25 
μM) and then maintained in culture with the same drug 
at the concentration of 1.25 μM, which mimics the dose 
commonly used to treat neuroblastoma patients [18].
It should be noted that in all experiments the 
acutely-etoposide treated HTLA and the chronically-
etoposide-treated HTLA (HTLA-Chr) were compared to 
the untreated parental HTLA, the cells from which both 
populations derive.
As shown in Figure 1A, the proliferation rate of 
HTLA cells, treated with 1.25 μM etoposide for 24 or 48 
hrs, was significantly reduced compared to the untreated 
control cells. Untreated and 24 hr-1.25 μM etoposide-
treated HTLA-Chr had a proliferative capacity similar to 
that of acutely-treated HTLA (Figure 1A). However, after 
48 hrs of etoposide treatment, the proliferation index of 
HTLA-Chr cells was higher than that of HTLA (Figure 1A).
Moreover, the tumorigenic potential of HTLA, 
indicated by the ability to generate colonies, was reduced 
by 89% after 24 hrs of etoposide treatment whereas, after 
the same exposure, the clonogenicity of HTLA-Chr cells 
was only reduced by 50%, in respect to untreated HTLA 
cells, remaining 5-fold higher than that of acutely-treated 
parental cells (Figure 1B). The proliferation rate and the 
clonogenic potential of HTLA-Chr cells did not change 
after etoposide exposure (Figures 1A and 1B).
In addition, as shown in Figure 1C, 1.25 μM and 
100 μM etoposide treatment for 24 hrs induced apoptosis 
in HTLA parental cells but not in HTLA-Chr cells, as 
demonstrated by the PARP cleavage. Interestingly, the 
expression of γ-H2AX, a marker of DNA double-strand 
breaks, was induced after 2 hrs of 1.25 and 100 μM 
etoposide treatment in both cell populations while after 
24 hrs it was enhanced in HTLA cells but not detected in 
HTLA-Chr cells (Figure 1D).
The loss of γ-H2AX expression in etoposide-
treated HTLA-Chr cells was accompanied by a 7-9 fold 
up-regulation of PIM2, RAD54B, DDB1 and FEN1, four 
genes involved in DNA repair mechanism as shown by the 
microarray analysis (Table 1).
Considering the different response of the two 
cell populations to etoposide exposure, their ability of 
internalizing different amounts of etoposide, for the 
same given dose (1.25 μM), was evaluated. As shown in 
Supplementary Figure S1, the intracellular (panel A) and 
the extracellular (panel B) etoposide levels were similar 
in both cell lines and were constant throughout the 24 hrs 
of treatment.
Chronic etoposide treatment induces a multi-
drug resistant phenotype
To evaluate the degree of resistance to etoposide, 
HTLA and HTLA-Chr cells were exposed to increasing 
concentrations (1.25 μM-100 μM) of the drug for 24 hrs. 
As shown in Figure 2A, etoposide was cytotoxic for HTLA 
cells in a concentration-dependent manner. In fact, 10 μM 
etoposide decreased the viability of HTLA cells by 14% 
and the highest dose (100 μM) of the drug led to 35% of 
cell death. In HTLA-Chr, the cytotoxic effect was recorded 
only at the doses of 50 and 100 μM, with a 9% and 17% 
reduction in cell viability, respectively (Figure 2A).
To investigate the hypothesis of multi-drug 
resistance, HTLA parental and HTLA-Chr cells were 
exposed to doxorubicin, another chemotherapeutic drug 
commonly used in the therapy of neuroblastoma [19]. 
Figure 2B shows that 0.184 μM doxorubicin reduced 
the viability of HTLA parental cells by 44% only after 
72 hrs whilst did not affect the viability of HTLA-Chr 
cells. The highest doxorubicin dose (14.72 μM) was 
cytotoxic for both cell populations already after 24 hrs 
inducing 40% and 25% cell death in HTLA parental and 
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Figure 1: Chronically-etoposide-treated HTLA cells (HTLA-Chr) are less proliferating and tumorigenic than untreated 
HTLA parental cells and they evade apoptotic death induced by etoposide exposure. A. Proliferation assay. HTLA parental 
cells and HTLA-Chr cells were incubated with CFDA-SE and the intensity of cellular CFDA-SE fluorescence was evaluated at 24 hrs and 
48 hrs after 1.25 μM etoposide treatment. Results were expressed as proliferation index and are the means ±S.E.M. of three independent 
experiments. **p<0.01 vs. 24 hrs untreated HTLA cells; °°p<0.01 vs. 1.25 μM 48 hrs etoposide-treated HTLA cells; ##p<0.01 vs. 24 hrs; 
§§p<0.01 vs. 48 hrs untreated HTLA cells. B. Clonogenic assay. HTLA parental cells and HTLA-Chr cells were seeded in six-well plates and 
then incubated with 1.25 μM etoposide for 24 hrs. Subsequently, cells were incubated in fresh medium without the drug for an additional 
20 days before staining and counting the colonies. The histogram summarizes quantitative data of the means ± S.E.M. of four independent 
experiments. **p<0.01 vs. untreated HTLA cells; °°p<0.01 vs. 1.25 μM etoposide treated HTLA cells. C. Protein levels of PARP in HTLA 
and HTLA-Chr cells treated for 24 hrs with 1.25 and 100 μM etoposide. Immunoblots shown are representative of three independent 
experiments. β-Actin is the internal loading control. D. Protein levels of γ-H2AX and H2AX in HTLA and HTLA-Chr cells treated for 2 
hrs (upper panels) or for 24 hrs (lower panels) with 1.25 and 100 μM etoposide. Immunoblots shown are representative of three independent 
experiments. β-Actin is the internal loading control.
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HTLA-Chr cells, respectively. Cell viability was further 
decreased after 48 hrs of treatment, and reached 90% and 
70% of reduction in HTLA parental and HTLA-Chr cells, 
respectively, after 72 hrs (Figure 2B).
H2O2 exposure (3 hrs) also induced a concentration-
dependent reduction of cell viability in both cell 
populations (Figure 2C) and yet, cytotoxicity was higher 
in HTLA parental cells where 1000 μM H2O2 reduced the 
viability by 66% compared to 44% of HTLA-Chr cells.
In order to confirm the MDR phenotype of HTLA-
Chr cells, a microarray analysis of genes involved in 
MDR system was performed. Among these genes, ARNT, 
Ezrin, ABCB6 and BCRP1 (also known as ABCG2), 
were found to be over-expressed (about 5-15-fold) in 
1.25 μM etoposide-treated HTLA-Chr cells in respect to 
etoposide-treated parental cells (Table 2). These results 
were confirmed by a real time PCR analysis (Table 2).
Exposure to etoposide or doxorubicin does 
not stimulate the ability of HTLA-Chr cells to 
produce H2O2
As shown in Figure 3A, 24 hr etoposide treatment 
of HTLA parental cells increased the production of 
H2O2in a concentration-dependent manner. In particular, 
compared to untreated HTLA cells, the intracellular 
peroxide concentration was increased by 88% at the dose 
of 1.25 μM and further increased by 2-fold at the doses 
of 50 and 100 μM. Interestingly, the same treatments did 
not stimulate the production of H2O2 in HTLA-Chr cells 
(Figure 3A). A similar result was observed when treating 
the two cell populations with increasing concentrations of 
doxorubicin (Figure 3B).
To investigate the role of cell metabolism in H2O2 
generation, the oxygen consumption rate (OCR) and ATP 
synthesis were measured. We found that in etoposide-
treated HTLA-Chr cells, such parameters were decreased 
by 34% and 44%, respectively, in comparison to untreated 
HTLA parental cells, but they were almost abolished 
in HTLA parental cells acutely-treated with etoposide 
(Figures 4A and 4B). Moreover, the OCR and ATP 
synthesis were similar in etoposide-treated HTLA-Chr and 
in untreated HTLA-Chr cells (Figures 4A and 4B).
To verify the efficiency of the oxidative 
phosphorylation, the P/O value was evaluated (Figure 4C). 
In untreated and etoposide-treated HTLA-Chr cells, the 
P/O ratio was 2.3±0.2 which was comparable to the 
physiological level (2.5) reported by Hinkle [20]. By 
contrast, in acutely-treated HTLA parental cells, the P/O 
value was lower (1.7±0.15) suggesting that a part of the 
oxygen consumption could be attributed to the production 
of H2O2.
Moreover, in order to verify the energetic cellular 
status, the ATP/AMP ratio was evaluated. As shown 
in Figure 4D, the ATP/AMP ratio was reduced by 25% 
in etoposide-treated HTLA-Chr cells and by 67% in 
acutely-treated HTLA parental cells, confirming that in 
the latter case, the oxidative phosphorylation was not 
Table 1: Microarray analysis of the DNA repair genes over-expressed in 24 hr etoposide-treated HTLA-Chr cells in 
comparison with etoposide-treated HTLA parental cells
Gene name Function A)














serine-threonine kinase which 
mediates DNA damage response 
via ATR
[91]
4.16 0.48 8.74 ± 1.1
RAD54B
scaffold for p53 degradation 
facilitating its ubiquitination
[92]
6.56 0.78 8.66 ± 2.0
DDB1
protein involved in the 
nucleotide excision repair
[93]
11.24 1.62 6.94 ± 1.4
FEN1
endonuclease that recognizes 
and cleaves one nucleotide 
into the double-stranded DNA 
junctions
[94]
9.860 1.40 7.22 ± 2.3
PIM2, proviral integrations of Moloney virus; DDB1, DNA damage-binding protein 1; FEN1, flap endonuclease 1.
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Figure 2: HTLA-Chr cells develop a multi-drug resistant phenotype. Cell viability was determined by MTT assays in cells 
exposed to increasing concentrations of etoposide (1.25–100 μM) for 24 hrs A. of doxorubicin (0.046-14.72 μM) for 24, 48 and 72 hrs 
B. and of H2O2 (250-1000 μM) for 3 hrs C. Histograms summarize quantitative data of the means ± S.E.M. of four independent experiments. 
*p<0.05 vs. untreated HTLA cells (Ctr); **p<0.01 vs. untreated HTLA cells (Ctr); °p<0.05 vs. treated HTLA cells; °°p<0.01 vs. treated 
HTLA cells; §p<0.05 vs. untreated HTLA-Chr cells (Ctr); §§p<0.01 vs. untreated HTLA-Chr cells (Ctr).
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completely efficient. Also in this case, the ATP/AMP ratio 
in etoposide-treated HTLA-Chr cells was comparable to 
that of untreated HTLA-Chr (Figure 4D).
In addition, the rate of glucose consumption, lactate 
formation, as well as the activity of lactate dehydrogenase 
(LDH), increased by 56%, 77% and 164%, respectively 
in acutely-treated HTLA parental cells (Figure 4E, 4F 
and 4G), suggesting that the impairment of oxidative 
phosphorylation could be partially compensated by an 
increment in the anaerobic glycolytic rate.
Since the amount of peroxides is a balance 
between the mitochondrial ROS formation and ROS 
detoxification, the status of the main antioxidant enzymes 
was investigated.
Due to the fact that the gene expression profile 
analysis demonstrating that SOD1 and catalase expression 
had been increased by 67% and 71%, respectively in 
etoposide-treated HTLA-Chr cells compared to acutely-
treated parental ones, both enzymatic activities were 
measured. While total SOD activity was increased by 
17% in both etoposide-treated parental and HTLA-Chr 
cells (Figure 4H), catalase activity was reduced by 42% in 
acutely-treated HTLA and stimulated by 49% in HTLA-
Chr cells exposed to etoposide in respect to HTLA parental 
ones (Figure 4H). Moreover, SOD and catalase activities 
in etoposide-treated HTLA-Chr cells were comparable to 
those of untreated HTLA-Chr (Figure 4H).
HTLA-Chr cells detoxify H2O2 and prevent 
lipid peroxidation by enhancing GSH levels and 
up-regulating GST activities
In untreated and in etoposide-treated HTLA-Chr 
cells, GSH levels were increased by 85% in respect to 
both untreated and acutely-treated parental cells while no 
difference in GSSG levels was observed (Figure 5A).
The analysis of γ-glutamyl-cysteinyl ligase 
(GCL) expression, a crucial enzyme involved in GSH 
biosynthesis, showed that the mRNA of catalytic subunit 
(GCLC) was up-regulated by 20% in untreated and 
etoposide-treated HTLA-Chr cells compared to HTLA 
parental ones (Supplementary Figure S2). Conversely, 
the protein level of GCLC was down-regulated by 85% 
in untreated and etoposide-treated HTLA-Chr cells in 
comparison to HTLA parental ones (Supplementary 
Figure S2). However, mRNA and protein levels of GCLM 
(modulatory subunit) were similar in parental HTLA and 
HTLA-Chr cells (data not shown).
In conformity with the trend of GSH levels, the 
production of MDA, a known lipid peroxidation marker, 
was increased by 72% in acutely-treated parental cells 
in respect to untreated ones while it did not change in 
untreated and etoposide-treated HTLA-Chr cells which 
maintained the levels found in parental cells (Figure 5B).
Since GSH amount was different in the cell 
populations analyzed, the expression and the activity of 
glutathione S-transferase (GST), a phase II detoxification 
enzyme that catalyzes the conjugation of GSH with 
exogenous and endogenous electrophilic substrates, was 
investigated. In fact, microarray analysis showed that the 
GST gene in etoposide-treated HTLA-Chr cells was over-
expressed by 2.2-fold in respect to acutely-treated parental 
cells and in accordance with this data, GST activity was 
increased 2-fold (Figure 5C).
GSH depletion by BSO increases H2O2 levels and 
markedly reduces the tumorigenic potential of 
HTLA-Chr cells
In order to test the role of GSH in the acquisition 
of drug resistance, both HTLA parental and HTLA-Chr 
cells were pre-treated for 1 hr with 1 mM L-buthionine-
sulfoximine (BSO), a GSH depleting agent and then 
exposed to etoposide for 24 hrs.
As shown in Figure 6A, exposure to 1 mM BSO 
alone reduced the GSH levels of parental cells by 65%. 
Moreover, BSO reduced the GSH content of parental 
and HTLA-Chr cells, treated for 24 hrs with 1.25 μM 
Table 2: Microarray analysis of the MDR genes over-expressed in 24 hr etoposide-treated HTLA-Chr cells in 
comparison with etoposide-treated HTLA parental cells
Gene name A)














ARNT 8.004 0.527 15.2 ± 1.7 3.47 ± 1.0
Ezrin 6.469 0.687 9.4 ± 0.9 2.15 ± 0.6
ABCB6 5.419 0.859 6.3 ± 0.5 4.08 ± 1.5
BCRP1 4.746 0.899 5.15 ± 0.6 3.34 ± 0.7
ARNT, Aryl Hydrocarbon receptor Nuclear Translocator; BCRP1/ABCG2, Breast Cancer Resistance Protein 1; ABCB6, 
mitochondrial ATP binding cassette transporter 6.
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Figure 3: HTLA-Chr cells do not change H2O2 production after treatment with etoposide or doxorubicin. H2O2 
production was analyzed in HTLA and in HTLA-Chr cells incubated for 24 hrs with increasing concentrations of etoposide (1.25–100 μM) 
A. or doxorubicin (0.046-14.72 μM) B. Histograms summarize quantitative data of the means ± S.E.M. of three independent experiments. 
*p<0.05 vs. untreated HTLA cells (Ctr); **p<0.01 vs. untreated HTLA cells (Ctr); °p<0.05 vs. treated HTLA cells; °°p<0.01 vs. treated 
HTLA cells.
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etoposide, by 63% and 70%, respectively (Figure 6A). 
BSO-induced changes in GSH levels were comparable 
in etoposide-treated HTLA-Chr cells and in untreated 
HTLA-Chr (Figure 6A).
In observing Figure 6B, BSO treatment decreased 
the parental cell viability by 14% compared to control 
and sensitized them to etoposide. Inversely, BSO did not 
modify the sensitivity of HTLA-Chr cells to the cytotoxic 
drug (Figure 6B).
As shown in Figure 6C, parental cells, treated 
with BSO, increased H2O2 production by 3.2-fold 
compared to untreated parental ones. Moreover, in 
the same cells, BSO-etoposide co-treatment increased 
peroxide levels by 2.4-fold in respect to the etoposide 
alone (Figure 6C). Similarly, in HTLA-Chr cells, BSO 
co-treatment stimulated H2O2 production by 2.6-fold 
compared to etoposide-treated HTLA-Chr cells (Figure 
6C). BSO-mediated peroxide over-production was similar 
in etoposide-treated HTLA-Chr cells and in untreated 
HTLA-Chr (Figure 6C).
BSO treatmentper se did not affect the clonogenic 
potential of HTLA parental cells, but almost abolished 
the clonogenicity of the same cells acutely-exposed to 
etoposide while reduced the clonogenicity of etoposide-
treated HTLA-Chr cells by 73% (Figure 6D). The 
reduction of clonogenic potential by BSO was found to be 
comparable in etoposide-treated HTLA-Chr cells and in 
untreated ones (Figure 6D).
Increasing GSH by NAC prevents H2O2 increase 
and markedly enhances the tumorigenic 
potential of HTLA-Chr cells
In order to further investigate the role of GSH in 
drug resistance, both cell populations were pre-treated for 
1 hr with 2 mM N-Acetylcysteine (NAC), an aminothiol 
Figure 4: HTLA-Chr cells have a major oxygen consumption, an increased oxidative phosphorylation and an 
up-regulation of catalase activity. A. The oxygen consumption rate (OCR) was evaluated in untreated and in 1.25 μM etoposide-
treated (24 hrs) HTLA and HTLA-Chr cells. Results were reported as nmol O2/min/10
6 cells. Histogram summarizes quantitative data of 
means ± S.E.M. of three independent experiments. **p<0.01 vs. untreated HTLA cells; °°p<0.01 vs. 1.25 μM etoposide-treated HTLA cells. 
B. ATP synthesis was measured in untreated and in 1.25 μM etoposide-treated (24 hrs) HTLA and HTLA-Chr cells. Results were reported 
as nmol ATP/min/106 cells. Histogram summarizes quantitative data of means ± S.E.M. of three independent experiments. **p<0.01 vs. 
untreated HTLA cells; °°p<0.01 vs. 1.25 μM etoposide-treated HTLA cells. C. P/O is expressed as the ratio of nmol of ATP, measured by 
luminometry in 1 minute over nmol of O2 consumed in 1 minute in the presence of the substrate + ADP. **p<0.01 vs. untreated HTLA cells; 
°°p<0.01 vs. 1.25 μM etoposide-treated HTLA cells. D. ATP and AMP were evaluated in untreated and in 1.25 μM etoposide-treated (24 
hrs) HTLA and HTLA-Chr cells. Histogram summarizes quantitative data of means ± S.E.M. of three independent experiments. **p<0.01 
vs. untreated HTLA cells; °°p<0.01 vs. 1.25 μM etoposide-treated HTLA cells. (Continued )
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and synthetic precursor of intracellular cysteine and then 
exposed to etoposide for 24 hrs.
As shown in Figure 7A, NAC increased the GSH 
levels of parental cells by 200%. Moreover, this rate of 
increase reached 500% when the cells having been pre-
treated with NAC were exposed for 24 hrs to etoposide. 
However, a more modest effect was observed in etoposide-
treated HTLA-Chr cells where NAC co-treatment 
increased GSH levels by 100% (Figure 7A). NAC partially 
protected parental cells from the cytotoxicity induced by 
50 μM etoposide but it did not modify the viability of 
HTLA-Chr cells (Figure 7B).
In addition, NAC reduced the peroxide production 
in HTLA and HTLA-Chr cells by 28% and, in the acutely-
etoposide-treated HTLA cells, by 55% (Figure 7C). A 
similar, but less marked effect was observed in etoposide-
treated HTLA-Chr cells (Figure 7C).
NAC alone was able to increase the clonogenic 
potential of parental cells by 45% and of HTLA-Chr cells 
by 110% (Figure 7D) and this effect was more evident 
in cells co-treated with etoposide. In particular, NAC-
etoposide co-treatment increased the clonogenicity of both 
acutely and chronically-etoposide-treated HTLA cells by 
300% and 126%, respectively (Figure 7D).
DISCUSSION
Neuroblastoma, the second most common childhood 
solid malignant tumor, is clinically characterized by a wide 
heterogeneity. To date, several drugs are available and 
among them etoposide, an inhibitor of topoisomerase II, is 
the standard clinically-used chemotherapeutic compound. 
Initially, patients are sensitive to this drug but unfortunately 
about 15-20% of them develop chemoresistance [13, 14, 21].
Figure 4: (Continued ) HTLA-Chr cells have a major oxygen consumption, an increased oxidative phosphorylation and 
an up-regulation of catalase activity. E. Glucose consumption was evaluated in untreated and in 1.25 μM etoposide-treated (24 hrs) 
HTLA and HTLA-Chr cells. Results were reported as mM glucose/106 cells. Histogram summarizes quantitative data of means ± S.E.M. of 
three independent experiments. **p<0.01 vs. untreated HTLA cells; °°p<0.01 vs. 1.25 μM etoposide-treated HTLA cells. F. Extracellular 
lactate concentration was evaluated in untreated and in 1.25 μM etoposide-treated (24 hrs) HTLA and HTLA-Chr cells. Results were reported 
as mM lactate/106 cells. Histogram summarizes quantitative data of means ± S.E.M. of three independent experiments. **p<0.01 vs. untreated 
HTLA cells; °°p<0.01 vs. 1.25 μM etoposide-treated HTLA cells. G. Lactate dehydrogenase activity (LDH) was evaluated in untreated and 
in 1.25 μM etoposide-treated (24 hrs) HTLA and HTLA-Chr cells. Results were reported as U/mg (lactate μmol/min/mg of total protein). 
Histogram summarizes quantitative data of means ± S.E.M. of three independent experiments. **p<0.01 vs. untreated HTLA cells; °°p<0.01 
vs. 1.25 μM etoposide-treated HTLA cells. H. Catalase and SOD activities in untreated and in 1.25 μM etoposide-treated (24 hrs) HTLA 
and HTLA-Chr cells. Histograms summarize quantitative data of means, normalized to the activity of enzymes in untreated cells (100%) ± 
S.E.M. of three independent experiments. **p<0.01 vs. untreated HTLA cells; °°p<0.01 vs. 1.25 μM etoposide-treated HTLA cells.
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Figure 5: HTLA-Chr cells are characterized by higher GSH levels, a lower amount of a lipid peroxidation marker and 
up-regulation of GST activity. A. Reduced and oxidized glutathione (GSH and GSSG) levels were analyzed in untreated and in 1.25 
μM etoposide-treated (24 hrs) HTLA and HTLA-Chr cells. Results were reported as μM/μg protein. Histogram summarizes quantitative 
data of means ± S.E.M. of six independent experiments. **p<0.01 vs. untreated HTLA cells; °°p<0.01 vs. 1.25 μM etoposide-treated HTLA 
cells. B. MDA production was evaluated in untreated and in 1.25 μM etoposide-treated (24 hrs) HTLA and HTLA-Chr cells. Results were 
reported as μM/mg protein. Histogram summarizes quantitative data of means ± S.E.M. of three independent experiments. **p<0.01 vs. 
untreated HTLA cells; °°p<0.01 vs. 1.25 μM etoposide-treated HTLA cells. C. GST analysis in untreated and in 1.25 μM etoposide-treated 
(24 hrs) HTLA and HTLA-Chr cells. Results were reported as μmol/mg prot/min. of reaction product taking into account the conjugated 
5-thio-2-nitrobenzoic acid molar extinction coefficient corresponding to 9.6 mol-1cm-1. Results are the mean ± S.E.M. of six independent 
analyses. **p<0.01 vs. untreated HTLA cells; °°p<0.01 vs. 1.25 μM etoposide-treated HTLA cells.
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In order to investigate the molecular mechanisms 
of chemoresistance, we chronically exposed a MYCN-
amplified human neuroblastoma cell line, isolated 
from a stage IV patient, to etoposide [22]. By using a 
concentration of etoposide that mimics the clinically-
used dose [18], we selected a cell population which might 
represent a good model for studying chemoresistance in 
vitro. In a previous study, Urbani et al. selected MYCN 
non-amplified neuroblastoma cells resistant to etoposide 
and they identified by proteomic analysis some potential 
markers of drug resistance such as Hsp27, beta-galactoside 
soluble lectin binding protein, vimentin, heterogeneous 
nuclear ribonucleoprotein K and peroxiredoxin [23]. The 
microarray analysis of gene profile in HTLA-Chr cells 
shows that the expression of these markers is not modified. 
Therefore, we believe that the discrepancy between our 
results and those of Urbani et al. might be due to the fact 
that HTLA-Chr cells are MYCN-amplified, while SH-
SY-5Y cells, the neuroblastoma line used by Urbani, are 
MYCN-unamplified. In support of the influence exerted 
by MYCN on the induction of a different gene profile, 
an inverse correlation between MYCN amplification and 
Hsp27 has been described [24] and this data might well 
explain the overexpression of this protein in SH-SY-5Y-
resistant cells but not in HTLA-Chr cells. Moreover, it 
has been found that SH-SY-5Y neuroblastoma cells do not 
Figure 6: BSO treatment induces GSH depletion, increases H2O2 production and markedly reduces the tumorigenic potential 
of etoposide-resistant cells. A. GSH levels were analyzed in HTLA and HTLA-Chr cell treated with 1 mM BSO or pre-treated (1 hr) with 1 
mM BSO and then exposed (24 hrs) to 1.25 μM etoposide. Results were reported as μM/μg protein. Histogram summarizes quantitative data of 
the means ± S.E.M. of three independent experiments. **p<0.01 vs. untreated HTLA cells; §§p<0.01 vs. untreated HTLA-Chr cells; °°p<0.01 vs. 
1.25 μM etoposide-treated HTLA cells; ̂ ^p<0.01 vs. 1.25 μM etoposide-treated HTLA-Chr cells. B. Cell viability was determined by MTT assays 
in HTLA and HTLA-Chr cells treated with 1 mM BSO or pre-treated (1 hr) with 1 mM BSO and then exposed (24 hrs) to 1.25 μM etoposide. 
Histogram summarizes quantitative data of the means ± S.E.M. of four independent experiments. *p<0.05 vs. untreated HTLA cells; **p<0.01 vs. 
untreated HTLA cells; °p<0.05 vs. 1.25 μM etoposide-treated HTLA cells; ççp<0.01 vs. HTLA cells pre-treated with 1 mM BSO and then exposed 
to 1.25 μM etoposide. C. H2O2 production was analyzed in HTLA and HTLA-Chr cells treated with 1 mM BSO or pre-treated (1 hr) with 1 
mM BSO and then exposed (24 hrs) to 1.25 µM etoposide. Histogram summarizes quantitative data of the means ± S.E.M. of four independent 
experiments. ** p<0.01 vs. untreated HTLA cells; °° p<0.01 vs. etoposide-treated HTLA cells; §§p<0.01 vs. untreated HTLA-Chr cells; ̂ ^p<0.01 
vs. 1.25 µM etoposide-treated HTLA-Chr cells. (Continued ) 
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express vimentin [25] and that the selection with etoposide 
is able to stimulate vimentin which is basally expressed 
in HTLA cells [26]. Although useful, Urbani’s model was 
not representative of the more aggressive and therapy-
refractory forms of neuroblastoma, characterized by the 
amplification of the MYCN proto-oncogene [27–30].
Herein, we demonstrate that HTLA-Chr cells 
are less proliferating than parental cells. This is in line 
with a previous report showing that anticancer therapy, 
administered for a prolonged period, leads cancer cells into 
a slow proliferating state, rendering them less sensitive to 
chemotherapy-induced effects [31].
In addition, HTLA-Chr cells are more tumorigenic 
than parental cells acutely treated with etoposide, and 
become resistant to the pro-apoptotic effect of etoposide so 
demonstrating that the chronic treatment with the drug is 
able to select a more malignant cell population. Although 
etoposide in all cell populations is internalized in similar 
amounts, only HTLA-Chr cells survive under etoposide 
treatment thanks to their ability to efficiently repair DNA 
damage and so evading the apoptotic death. In fact, the 
microarray analysis shows that genes such as PIM2, 
RAD54B, DDB1 and FEN1 involved in DNA repair, are 
overexpressed in HTLA-Chr cells which become resistant 
to the genotoxic effect of etoposide. A similar over-
expression of DNA repair genes has been observed also 
in tumor cells that were resistant to cisplatin treatment 
[32]. Therefore, our findings are consistent with other 
studies which report that an efficient ability to repair DNA 
damage results in chemoresistance [33] while a defective 
DNA repair capacity is responsible for the cytotoxic effect 
of drugs [34].
Based on the fact that chemoresistance often 
transforms into multi-drug resistance (MDR), which 
characterizes highly malignant neuroblastoma [35, 36], 
HTLA-Chr and parental cells were exposed to high doses 
of etoposide or doxorubicin using concentrations equal to, 
or higher than, those used to treat patients [18, 37].
Our results clearly show that HTLA-Chr cells 
acquire the MDR phenotype in that they are less sensitive 
than parental cells to high doses of either etoposide or 
doxorubicin. Etoposide and doxorubicin-induced cell 
death is, at least in part, mediated by oxidative stress [15, 
38–40]. Interestingly, we have demonstrated that HTLA-
Chr cells are less sensitive to pro-oxidant treatments 
(i.e. etoposide or doxorubicin or even H2O2) than the 
parental cells. Moreover, the analysis of the impact by 
chemotherapeutic drugs on the cellular oxidative status 
revealed that HTLA-Chr cells maintain basal levels of 
H2O2 after treatment with etoposide or doxorubicin, 
whereas the parental cells markedly increase their H2O2 
production. Accordingly, recent findings demonstrate 
that, although most of the anticancer drugs kill cancer 
cells by inducing oxidative stress, prolonged treatments 
lead to a reduced oxidative stress as a consequence of 
therapy resistance [41, 42]. It was also demonstrated 
that the acquisition of chemoresistance in gliomas is 
associated with decreased ROS production and increased 
mitochondrial coupling [43]. In our study, HTLA-Chr 
cells show a high respiratory rate in terms of oxygen 
consumption and P/O ratio which could explain the 
lower peroxide production. In line with this hypothesis, 
the high efficiency of aerobic metabolism in HTLA-Chr 
cells is paralleled by a lower anaerobic glycolytic rate as 
Figure 6: (Continued ) BSO treatment induces GSH depletion, increases H2O2 production and markedly reduces the 
tumorigenic potential of etoposide-resistant cells. D. Clonogenic assay was carried out in HTLA and HTLA-Chr cells treated with 
1mM BSO or pre-treated (1 hr) with 1 mM BSO and then exposed (24 hrs) to 1.25 μM etoposide. Subsequently, cells were incubated in 
fresh medium without the drug for an additional 20 days before staining and counting the colonies. The histogram summarizes quantitative 
data of the means ± S.E.M. of three independent experiments. **p<0.01 vs. untreated HTLA cells; °°p<0.01 vs. etoposide-treated HTLA 
cells; §§p<0.01 vs. untreated HTLA-Chr cells; ^^p<0.01 vs. 1.25 μM etoposide-treated HTLA-Chr cells; ##p<0.01 vs. 1mM BSO-treated 
HTLA cells; ççp<0.01 vs. HTLA cells pre-treated with 1 mM BSO and then exposed to 1.25 μM etoposide.
Oncotarget70727www.impactjournals.com/oncotarget
measured in terms of lactate formation, LDH activity and 
glucose consumption.
Another strategy developed by cancer cells in order 
to maintain peroxides within non-toxic levels is that of up-
regulating scavenging enzymes, such as SOD and catalase, 
also involved in drug resistance [44–47].
Our results, showing that chronic etoposide 
treatment strongly increases the activity of catalase, 
which degrades peroxides,contribute to explaining the 
reduced presence of H2O2 in HTLA-Chr cells. These 
findings are also in line with a study demonstrating that 
chemoresistance of lymphoma cells results from the 
concomitant increase of SOD, which generates H2O2, and 
catalase activity [48].
To further investigate the antioxidant systems of 
our cellular model, we analyzed the role of glutathione 
(GSH), an ubiquitous thiol involved in detoxification, 
redox regulation and cellular signaling [16]. In 
accordance with the fact that GSH conjugation may 
be responsible for drug-resistant phenotypes and non-
Figure 7: NAC treatment enhances GSH levels, decreases H2O2 production and markedly promotes the tumorigenic 
potential of neuroblastoma cells. A. GSH levels were analyzed in HTLA and HTLA-Chr cells treated with 2 mM NAC or pre-treated 
(1 hr) with 2 mM NAC and then exposed (24 hrs) to 1.25 μM etoposide. Histogram summarizes quantitative data of the means ± S.E.M. 
of three independent experiments. **p<0.01 vs. untreated HTLA cells; §§p<0.01 vs. untreated HTLA-Chr cells; °°p<0.01 vs. 1.25 μM 
etoposide-treated HTLA cells, ^^p<0.01 vs. 1.25 μM etoposide-treated HTLA-Chr cells. B. Cell viability was determined by MTT assays 
in HTLA and HTLA-Chr cells treated with 2 mM NAC or pre-treated (1 hr) with 2 mM NAC and then exposed (24 hrs) to 1.25 μM and 
50 μM etoposide. Histogram summarizes quantitative data of the means ± S.E.M. of four independent experiments. **p<0.01 vs. untreated 
HTLA cells; ##p<0.01 vs. 50 μM etoposide-treated HTLA cells; ++p<0.01 vs. HTLA cells. C. H2O2 production was analyzed in HTLA and 
HTLA-Chr cells treated with 2 mM NAC or pre-treated (1 hr) with 2 mM NAC and then exposed (24 hrs) to 1.25 μM etoposide. Histogram 
summarizes quantitative data of means ± S.E.M. of four independent experiments. **p<0.01 vs. untreated HTLA cells; °°p<0.01 vs. 
etoposide-treated HTLA cells; §§p<0.01 vs. untreated HTLA-Chr cells; ^^p<0.01 vs. 1.25 μM etoposide-treated HTLA-Chr cells; çp<0.05 
vs. HTLA cells pre-treated with NAC and then exposed to 1.25 μM etoposide. (Continued ) 
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responsiveness of brain tumors to alkylating agents 
[49], our results demonstrate that HTLA-Chr cells are 
characterized by higher levels of GSH, compared to 
untreated and acutely-etoposide treated parental cells. 
This is in accordance with other findings stating that high 
levels of GSH in tumors are linked to the development 
and expression of MDR [50] and elevated levels of GSH 
are directly correlated with resistance to camptothecin 
(CPA) and 4-hydroperoxy-CPA (4-HC) in a panel of 
medulloblastoma cell lines [51].
In our context, however, the high amount of 
GSH in HTLA-Chr cells is not directly related to an 
increased expression of g-glutamyl-cysteinyl ligase 
(GCL), a rate-limiting enzyme in GSH biosynthesis 
[52]. In fact, our findings, also in line with a recent study 
[53], demonstrate that the increase in GCLC mRNA is 
followed by a decrease in GCLC protein level, whereas 
GCLM mRNA and protein level have a similar trend of 
expression.
Some authors suggest that GSH-mediated drug 
resistance might be the consequence of changes in 
GSH-related enzyme activities [51, 54, 55]. In detail, 
it has been demonstrated that cancer cells resistant 
to 1,3-bis(2-chloroethiyl)-1-nitrosourea (BCNU) 
[54, 55] are characterized by high levels of GSH and 
a major activity of GST enzyme which promotes 
GSH conjugation with the drug contributing to its 
inactivation [54]. In addition, chemoterapy-resistant 
orthotopic xenografts of nonsmall cell lung carcinoma 
were seen to express high GST levels [56] and in 
accordance with these observations, our own results 
show that HTLA-Chr cells have a higher GST level/
activity than the parental cells.
Therefore, our data leads us to hypothesizing that 
the MDR of HTLA-Chr cells is dependent on GSH, since 
it is responsible for the increase in GST activity which 
is potentially involved in the acquisition of the MDR 
phenotype.
Among MDR genes analyzed, we have taken 
into consideration the genes related to GSH and over-
expressed in HTLA-Chr cells. In particular, ARNT 
(Aryl Hydrocarbon Receptor Nuclear Translocator) 
is a nuclear receptor which has been demonstrated 
to enhance antioxidant response and to confer drug 
resistance in leukemia cells [57]. ARNT is also 
involved in the up-regulation of BCRP1/ABCG2 
(Breast Cancer Resistance Protein 1) [58, 59], a drug 
transporter which can also mediate GSH transport [60]. 
Multidrug transporters include P-glycoprotein (Pgp), 
a protein efflux pump belonging to the ATP-binding 
cassette (ABC) superfamily, which binds to Ezrin, 
a cytoskeletal protein correlated with the metastatic 
phenotype and multidrug resistance of lymphoid cells 
[61]. Furthermore, the acquisition of chemoresistance in 
HTLA-Chr cells is associated with the overexpression 
of ABCB6 (ATP binding cassette transporter 6), a 
Figure 7: (Continued ) NAC treatment enhances GSH levels, decreases H2O2 production and markedly promotes the 
tumorigenic potential of neuroblastoma cells. D. Clonogenic assay was carried out in HTLA and HTLA-Chr cells treated with 2 
mM NAC or pre-treated (1 hr) with 2 mM NAC and then exposed (24 hrs) to 1.25 μM etoposide. Subsequently, cells were incubated in 
fresh medium without the drug for an additional 20 days before staining and counting the colonies. The histogram summarizes quantitative 
data of the means ± S.E.M. of three independent experiments. **p<0.01 vs. untreated HTLA cells; °°p<0.01 vs. etoposide-treated HTLA 
cells; §§p<0.01 vs. untreated HTLA-Chr cells; ^^p<0.01 vs. 1.25 μM etoposide-treated HTLA-Chr cells; ##p<0.01 vs. NAC-treated HTLA 
cells; ççp<0.01 vs. HTLA cells pre-treated with NAC and then exposed to 1.25 μM etoposide.
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mitochondrial drug transporter which is also correlated 
with the multidrug resistance in several cancer cells 
[62, 63].
On the basis of our results, etoposide chronic 
exposure is able to select a population of chemoresistant 
neuroblastoma cells overexpressing crucial genes of the 
MDR system and displaying an important GSH-mediated 
antioxidant defense that efficiently prevents the membrane 
lipoperoxidative impairment and cell death.
Interestingly, the modulation of GSH levels 
shows that BSO (an inhibitor of GSH biosynthesis) plus 
etoposide treatment markedly stimulates H2O2 over-
production and decreases the high tumorigenic potential 
of HTLA-Chr cells whilst NAC (a donor of cysteine 
groups) plus etoposide treatment reduces peroxide 
generation and increases the tumorigenicity. Our data 
confirms the important role of GSH in the sensitization 
of neuroblastoma [64–69], ovarian cancer [70], acute 
lymphoblastic leukemia [71] and other human cancer cells 
[72, 73] to traditional anticancer therapies.
Since it has been recently reported that the 
evaluation of oxidative stress status could be a marker 
of drug efficacy in cancer patients [17], we propose the 
monitoring of GSH levels and of GSH-related enzymes 
as potential tools to predict and control the patient’s 
response to therapy and to early identify the onset of drug 
resistance.
However, further studies are still needed to 
identify the molecular mechanisms underlying these cell 
responses which have not yet been fully explained. In 
fact, in considering that several molecules involved in 
the response of tumor cells to chemotherapy are redox-
modulated, given that they have functional cysteine 
groups and control key steps of the cell cycle and death, 
we believe that the identification of these “redox sensors” 
could be most useful in both the diagnosis and therapy of 
neuroblastoma.
MATERIALS AND METHODS
Cell cultures and treatments
The MYCN-amplified human stage-IV 
neuroblastoma cell line, HTLA-230, was obtained 
from Dr. V. Pistoia (G. Gaslini Institute, Genoa, Italy). 
The cell line was tested for mycoplasma contamination 
(Mycoplasma Reagent Set, Aurogene s.p.a, Pavia, Italy). 
After thawing and eight passages in the culture, cell 
morphology and proliferation were analyzed. Cells 
were cultured in RPMI 1640 (Euroclone SpA, Pavia, 
Italy) supplemented with 10% fetal bovine serum (FBS; 
Euroclone), 2 mM glutamine (Euroclone), 1% penicillin/
streptomycin (Euroclone), 1% sodium pyruvate (Sigma), 
and 1% of aminoacid solution (Sigma).
The Etoposide-Resistant cell line (HTLA-
Chr) was selected by treating HTLA-230 cells for 6 
months with increasing concentrations of etoposide 
(Calbiochem, Merck KGaA, Darmstadt, Germany; up 
to 1.25 μM), and then maintaining them in a medium 
supplemented with 1.25 μM etoposide, the dose 
comparable to that clinically used [18]. In parallel, a 
DMSO-R cell line was selected by treating HTLA-230 
cells for 6 months with the concentration of DMSO 
used to dissolve etoposide.
Parental HTLA-230 and HTLA-Chr cells were 
treated for 24 hrs with etoposide doses ranging from 
1.25 to 100 μM. In other experiments, cells were treated 
for 24, 48 and 72 hrs with increasing concentrations 
of doxorubicin (Sigma; 0.046-14.72 μM) or exposed 
for 3 hrs to increasing concentrations (250-1000 μM) 
of H2O2 (Carlo Erba, Milan, Italy). In another series of 
experiments, parental and HTLA-Chr cells were pre-
treated for 1 hr with 1 mM L-Buthionine sulfoximine 
(BSO, Sigma) or with 2 mM N-Acetylcysteine (NAC, 
Sigma) and then exposed to etoposide (1.25 and 50 μM) 
for 24 hrs.
The stock solutions of etoposide were prepared in 
DMSO and pilot experiments demonstrated that the final 
DMSO concentrations did not change any cell responses 
analyzed.
Cell proliferation assay
Cell proliferation was evaluated by staining cells 
with carboxyl fluorescein succinimidyl ester (CFDA-
SE, Invitrogen, Milan, Italy), a lipophilic dye that reacts 
with amino groups on peptides and proteins forming a 
stable amide bond, and detection by dye dilution assay 
in flow cytometry [68, 74, 75]. Cells were seeded in six-
well plates (Corning Incorporated, NY, USA), washed 
and incubated with 5 μM CFDA-SE in 10 mM PBS in 
the dark at 37 °C in 5% CO2 for 5 min. At the end of 
incubation, the cells were washed three times with 10 
mM PBS supplemented with 1% FBS. Then, the samples 
were exposed to the treatments. After 24 and 48 hrs, cells 
were washed and scraped-off in PBS and the intensity of 
CFDA-SE fluorescence was evaluated by flow cytometry. 
Proliferation of CFDA-SE-labeled cells was estimated by 
the progressive halving of cellular fluorescence as every 
cell division was completed. Samples were analyzed 
using a FACSCanto II flow cytometer by FacsDiva 
software version 6.0 (Becton Dickinson Italia, BD, 
Milan, Italy). The flow cytometry data files were analyzed 
using the Proliferation Wizard module of the ModFit 
LT 3.2 software (Verity Software House Inc., Topsham, 
ME, USA). The proportions of proliferated cells at 
each division were obtained by ModFit analysis, which 
generates histograms of fluorescence intensity by applying 
deconvolution algorithms [76]. The proliferation index is 
the ratio of the total number of divisions over the number 




Neuroblastoma cells (200 per well) were seeded 
in 6-well plates (Corning), left to attach as a monolayer 
and then treated. Subsequently, the medium was changed 
and the cells were maintained in drug-free medium for 20 
days. Cells were then fixed with methanol and stained with 
crystal violet (0.5 % in water with 50% methanol). Only 
colonies containing more than 30 cells were considered 
and the images were acquired with a Nikon Coolpix L22 
camera (NIKON Corporation, Tokyo, Japan).
Immunoblot analysis
Immunoblots were carried out according to standard 
methods [77] using rabbit antibody anti-PARP (Cell 
Signalling Technology Inc., Danvers, MA, USA Upstate, 
Lake Placid, NY, USA), anti-H2AX, anti-GCLC and 
anti-GCLM (Abcam, Cambridgeshire, UK) and mouse 
antibody anti-b-actin (Sigma) and anti-γ-H2AX (Abcam).
Anti-mouse and anti-rabbit secondary antibodies 
were coupled with horseradish peroxidase (GeHealthcare, 
Buckinghamshire, UK). Proteins were visualized with an 
enzyme-linked chemiluminescence detection kit according 
to the manufacturer’s (GeHealthcare) instructions. 
Chemiluminescence was monitored by exposure to film 
and the signals were analyzed under non-saturating 
conditions with an image densitometer connected to 
Quantity One software (Bio-Rad Laboratories, Hercules, 
CA, USA).
HPLC evaluation of etoposide levels
Etoposide was measured by HPLC with UV 
detection. The method was a modification of the method 
of Haim et al [78]. Aliquots of cell medium and of 
supernatant of cell extracts were diluted 1:1 with methanol, 
in order to obtain a 50% methanol solution [79]. HPLC 
was equipped with a Waters Spherisorb ODS2 column 
(particle diameter 5μm) [80]. The isocratic elutions were 
performed with a mobile phase constituted by 0.01M Na 
acetate buffer pH 3.8 and acetonitrile in 7/3 ratio. The flow 
rate was 1ml/min and the detection was by absorbance at 
250 nm. Peak identification and quantification were made 
by peak comparison with standard etoposide.
MTT assay
Cell viability was determined using the 
dimethylthiazolyl-2-5-diphenyltetrazolium bromide 
(MTT, Sigma) staining. Briefly, cells were seeded into 
96-well plates (Corning) and then treated. Next, the cells 
were incubated with 0.5 mg/ml MTT for 3 hrs at 37°C. 
After incubation, the supernatant was discarded, insoluble 
formazan precipitates were dissolved in HCl (0.1 N in 
isopropanol) and the absorbance at 570/630 nm was 
recorded using a microplate reader (EL-808, BIO-TEK 
Instruments Inc., Winooski, Vermont, USA).
Detection of hydrogen peroxide (H2O2) 
production
After treatment, cells were incubated with 5 μM 
2’-7’ dichlorofluorescein-diacetate (DCFH-DA; Sigma) 
and the accumulation of dichlorofluorescein (DCF) was 
analyzed by flow cytometry using a FACSCanto II flow 
cytometer (BD) using FlowJo (Tree Star, Inc). At least 
10,000 events were analyzed.
Evaluation of oxygen consumption rate
In order to measure the respiratory activity, 
2x105 cells were used for each experiment, using 
an amperometric O2 electrode in a closed chamber, 
magnetically stirred at 37 °C. The cells were suspended 
in a medium containing: 137 mM NaCl, 5 mM KH2PO4, 5 
mM KCl, 0.5 mM EDTA, 3 mM MgCl2 and 25 mM Tris–
HCl, pH 7.4, and permeabilized with 0,3% digitonin for 10 
min. Then, the sample was transferred to the chamber and 
to measure the maximum respiration rate, 5 mM pyruvate 
plus 2.5 mM malate were added.
Evaluation of ATP synthesis
ATP synthesis was measured by the highly-
sensitive luciferin/luciferase method [81]. Assay was 
carried out at 37°C over 2 min. by measuring formed 
ATP from added ADP. Cells were incubated for 10 min. 
in a medium containing: 10 mM Tris-HCl (pH 7.4), 50 
mM KCl, 1 mM EGTA, 2 mM EDTA, 5 mM KH2PO4, 2 
mM MgCl2, 0.6 mM Ouabain, 0.040 mg/ml Ampicillin, 
0.2 mM di(adenosine-5’) penta-phosphate, 0.2 mM and 
5 mM pyruvate plus 2.5 mM malate. Afterwards, ATP 
synthesis was induced by the addition of 0.3 mM ADP. 
The ATP content was measured using the luciferin/
luciferase ATP bioluminescence assay kit CLSII (Roche, 
Basel, Switzerland) on a Luminometer (Triathler, 
Bioscan,Washington, D.C.). ATP standard solutions 
(Roche, Basel, Switzerland) in the concentration range of 
10-10-10-7 M were used for calibration [82].
Assay of intracellular levels of ATP and AMP
Cells were washed twice with PBS and lysed 
with 2.5% perchloric acid (PCA) to block all enzymatic 
activities. After centrifugation, supernatants containing 
PCA were collected and neutralized with 0.2 M K2CO3.
ATP was assayed, following NADP reduction at 
340 nm. The medium contained 50 μg of neutralized cell 
homogenate, 50 mM Tris-HCl pH 8.0, 1 mM NADP, 10 
mM MgCl2, and 5 mM glucose in 1 ml final volume. 
Samples were analyzed by spectrophotometer before and 
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after the addition of 4 mg of purified hexokinase/glucose-
6-phosphate dehydrogenase.
AMP was evaluated following the NADH oxidation 
at 340 nm. The medium contained 50 μg of neutralized 
cell homogenate, 100 mM Tris-HCl (pH 8.0), 75 mM KCl, 
5 mM MgCl2, 0.2 mM ATP, 0.5 mM phosphoenolpyruvate, 
0.2 mM NADH, 10 IU adenylate kinase, 25 IU pyruvate 
kinase, and 15 IU of lactate dehydrogenase [83].
Evaluation of extracellular lactate
Lactate concentration was assayed by 
spectrophotometric analysis in the growth medium, 
following the reduction of NAD+ at 340 nm [84]. The 
assay medium contained 100 mM Tris/HCl (pH 8), 5 mM 
NAD+ and 1 IU/ml of lactate dehydrogenase. Samples 
were analyzed before and after the addition of 4 μg of 
purified lactate dehydrogenase. Data was normalized to 
the cell number.
Lactate dehydrogenase activity assay
Lactate dehydrogenase activity (LDH) was 
measured in the cell homogenate, obtained after sonication 
in PBS. The assay medium contained 100 mM Tris pH 
7.4, 0.15 mM NADH and 10 mM pyruvate. The enzymatic 
activity was monitored for 5 min., at 340 nm following the 
oxidation of NADH (angular coefficient for NADH at 340 
nm is ℇ=6.22 mM -1 cm-1) [85].
Evaluation of glucose consumption
Glucose consumption was evaluated by measuring 
supernatant concentration using a double beam 
spectrophotometer (UNICAM UV2, Analytical S.n.c., PR, 
Italy), by the hexokinase (HK) and glucose 6 phosphate 
dehydrogenase (G6PD) coupling system, following 
the reduction of NADP at 340 nm. The assay medium 
contained 100 mM Tris HCl, pH 7.4, 2 mM ATP, 10 mM 
NADP, 2 mM MgCl2, 2 IU of HK and 2 IU of G6PD. 
The reaction was started after the addition of 5 μl of cell 
medium.
Gene expression analysis by cDNA microarray
The expression of 18,401 human genes was tested 
by cDNA microarray. Custom microarrays, made available 
by the Microarray Department-University of Amsterdam, 
were used [86, 87]. The whole list of spotted genes is 
available on the website http://www.micro-array.nl/
libraries.html. All data is MIAME-compliant as detailed 
on the MGED Society website http://www.mged.org/
Workgroups/MIAME/miame.html. Used microarrays have 
been made available by the Microarray Department of the 
University of Amsterdam (http://www.micro-array.nl).
Purified RNA underwent reverse transcription 
and amplification using quantitative real-time PCR 
(qPCR) prior to probe synthesis for array hybridization. 
A retrotranscription protocol (SuperSMART, Clontech, 
Palo Alto, CA, USA) was applied as follows: RNA was 
incubated with a mix of a target sequence-oligo(dT)-
linked primer and a target sequence-oligo(dG)-linked at 
72°C for 5 min. and then a mastermix solution was added, 
containing reverse transcriptase and dNTPs mix. Samples 
were then incubated at 42°C for 90 min. Reaction was 
terminated by adding ethylenediaminetetraacetic acid, 
mixture diluted in phosphate buffer and synthesized cDNA 
purified by column chromatography using a commercially-
available purification kit (QIAquick PCR purification kit, 
Qiagen, Chatsworth, CA, USA).
The amplified cDNA, as purified by column 
chromatography, was converted into aminomodified 
oligonucleotides purified by column chromatography and 
alcohol precipitation and then labelled with fluorescent 
tracers Cy3 or Cy5 by incubation at room temperature in 
the dark for 90 min. Fluorescent oligonucleotides were 
precipitated by cold ethanol and sodium acetate, and then 
purified by column chromatography. The efficacy of the 
procedure was checked by spectrophotometric analysis 
measuring absorbance at 550 (Cy3) and 650 (Cy5) nm. 
Standardized amounts of labelled probes were hybridized 
on glass cDNA microarrays. Probes were lyophilized, 
diluted in 4 μl of EDTA 10 mM and incubated at 95°C 
for 10 min. Hybridization solution (18 μl) was added 
and the labelled probe was mixed together to a final 
volume of 44 μl. The mixture was then transferred onto 
microarrays which were then covered with a coverslip and 
hybridized overnight at 50°C in a Hybridization Cassette 
(Life Technologies, Carlsbad, CA, USA). After 16 hrs, 
the microarrays were washed twice in a low stringency 
wash buffer and twice in a high stringency wash buffer. 
The microarrays were dried in a centrifuge and the signal 
was acquired by a laser scanner (ScanArray, PerkinElmer, 
Waltham, MA, USA). Data analysis was performed 
subtracting the local spot background for each microarray 
from raw spot intensity, log transformation, normalization 
per chip and per array (GeneSpringH software, Agilent 
Technologies, Santa Clara, CA). Each gene was spotted in 
quadruplicate on the used microarray. Accordingly, results 
represent the mean among 4 sets of data. Data generated 
for each mRNA were compared among the various 
experimental groups by volcano-plot analysis taking into 
account thresholds of 1.5-fold variation and statistical 
significance (p 0.05) as evaluated by ANOVA after 
Bonferroni multiple-testing correction. Global mRNA 
expression profiles were compared by bidimensional 
principal component analysis of variance (PCA).
Real time RT PCR
SYBR green real time RT-PCR was performed for 
the validation of the data produced by microarray analysis. 
The primer sequences (TIB Molbiol, Italy) used are the 
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following: ARNT (F 5’-GATGCGATGATGACCAG 
ATGTG-3’; R 5’-CAGTGAGGAAAGATGGCTTGTA
GG-3’); EZRIN (F 5’-CGCAAGGAGGATGAAGTT-3’; 
R 5’-GGATGATGTCATTGTGGGTC-3’), ABC 
B6 (F 5′-CAGCAGGGACAGGAAGAA-3′; R 
5′-CCAAGACCAGGATGAAAT-3′) and BCRP-
1 (F 5’-TGGCTGTCATGGCTTCAGTA-3’; R 
5’-GCCACGTGATTCTTCCACAA-3’). To minimize 
primer-dimer formation, primer set concentration and 
thermocycling conditions were optimized (data not 
shown). cDNA was generated by using the Superscript 
II Reverse Transcription (LifeTechnologies, Carlsbad, 
California, USA) and following the manufacturer’s 
instructions. Then, the reaction mixture was incubated at 
65°C for 5 min. and then transferred into ice, centrifuged 
and added with 8 μl of the buffer containing 5x first strand 
buffer, 0.1M DTT, RNAse OUT and Superscript II.
The samples were incubated for 60 min. at 42°C 
and then, for 15 min. at 70°C. PCRs were performed 
on a Rotor-Gene 3000§ (Corbett Research, 1/14 Hilly 
St, Mortlake NSW 2137, Australia). Each reaction 
was carried out in a mixture containing 10x PCR 
buffer, 50mM MgCl2, dNTM mix, 10 μM primer A, 
10 μM primer S, Platinum® Taq DNA polymerase 
(LifeTechnologies), RT (cDNA 1:10 diluted) and 3x 
SYBR GREEN® (LifeTechnologies). The thermal profile 
consisted of hot-start enzyme activation at 95°C for 2 
min., followed by 45 cycles of PCR which consisted 
of the denaturation at 94°C for 45s, the annealing for 
30s (temperature reaction depends on the gene), and the 
elongation at 72°C for 30s. Each strain used was tested 
in triplicate. Each sample was submitted to two distinct 
reactions of q-PCR, with a pair of primers flanking 
the sequence of the gene of interest and the other with 
the pair of primers of house-keeper gene in order to 
normalize the relative amount of the gene of interest.
Catalase and SOD activity analysis
The enzymatic activity of catalase and SOD was 
evaluated by Catalase Activity Colorimetric/Fluorimetric 
Assay kit (BioVision, BioVision Incorporated, CA, 
U.S.A) and Superoxide Dismutase Activity Assay kit 
(BioVision), respectively, following the manufacturer’s 
instructions. Briefly, after treatments, 106 cells were 
homogenized in assay buffer (for catalase activity) or in 
ice-cold 0.1 M Tris/HCl, pH 7.4 containing 0.5% Triton 
X-100, 5 mM Beta-mercapto-Ethanol and 0.1 mg/ml 
PMSF. Subsequently, cell lysates were centrifuged and 
the supernatants were collected and used to evaluate the 
enzyme activities.
Reduced (GSH) and oxidized (GSSG) 
glutathione levels
After treatments, cells were detached and harvested in 
PBS solution and about 25% of cell suspension was used for 
protein dosage, the remaining 75% of cell suspension was 
mixed with the same volume of the precipitating solution (2 
mM EDTA, 0.61 N TCA and 0.02 N HCl) and centrifuged 
(Euroclone) at 4,000 rpm for 15 min. at 4°C.
The resulting supernatant was used to evaluate 
the GSH and GSSG contents by the reaction with 
o-phthalaldehyde (OPA) [88]. Standard solutions were 
prepared by dissolving GSH or GSSG in Redox Quenching 
Buffer (RQB) containing 20 mM HCl, 5 mM DTPA and 10 
mM ascorbic acid. Samples or standards (GSH or GSSG) 
were treated with 5% TCA-RQB solution. To evaluate 
GSSG levels, N-ethylmaleimide (7.5 mM in RQB) was 
added. Subsequently, 1 M potassium phosphate (KPi) 
buffer (pH 7.0) was added to all tubes and the samples were 
incubated for 5 min. at room temperature. For GSSG assay, 
100 mM dithionite-RQB was used and the samples were 
incubated for 60 min. at room temperature. Then, 0.1 M KPi 
buffer (pH 6.9) and OPA (5 mg/ml in methanol) were added 
and, after a 30 min. incubation at room temperature, sample 
fluorescence was monitored with a Perkin Elmer fluorimeter 
(Perkin Elmer Life and Analytical Sciences, Shelton, USA) 
at 365/430 nm.
RT-PCR analysis
Total RNA was extracted using TRIZOL reagent 
(LifeTechnologies, Carlsbad, California, USA) according 
to the manufacturer’s instructions. Total RNA (1 μg) was 
reverse-transcribed into cDNA by a random hexamer 
primer and SuperScript™ II Reverse Transcriptase 
(LifeTechnologies).
Amplification of cDNA by a polymerase chain 
reaction was performed using AmpliTaq Polymerase 
(LifeTechnologies) and specific primers for GCLC F 5′-
ATG GAG GTG CAA TTA ACA GAC-3′; GCLC R 5′-
ACT GCA TTG CCA CCT TTG CA-3′ (206 bp); GCLM 
F 5′-CCA GAT GTC TTG GAA TGC-3′; GCLM R 5′-TGC 
AGT CAA ATC TGG TGG-3′(408 bp); GAPDH F 5′-AGC 
CAC ATC GCT CAG ACA CC-3′; and GAPDH R 5′-TGA 
GGC TGT TGT CAT ACT TCT C-3′ (426 bp). Target 
cDNA was amplified as follows: 5 min. at 95°C and then 
30 cycles of amplification (GCLC: denaturation at 95°C 
for 45s, annealing at 56°C for 45s and extension at 72°C 
for 45s; GCLM: denaturation at 95°C for 45s, annealing 
at 54°C for 45s and extension at 72°C for 45s; GAPDH, 
denaturation at 95°C for 1 min., annealing at 59°C for 1 
min. and extension at 72°C for 1 min.). PCR products 
were separated by electrophoresis on 2 % agarose gel, pre-
stained with ethidium bromide, and then visualized under 
UV light and quantified by densitometric analysis by using 
a specific software (GelDoc, BioRad, Milan, Italy).
Glutathione-S-transferase (GST) activity 
analysis
GST activity was tested according to the method 
of De Flora et al. [89]. Briefly, cell homogenates, 
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containing 800 μg proteins, were incubated for 40 
min. at 37°C using 1-cloro 2,4-dinitroclorobenzene 
and reduced GSH (Sigma) as substrates. This 
reaction, catalyzed by GST, resulted in the production 
of conjugated 5-thio-2-nitrobenzoic acid whose 
absorbance was evaluated at 340 nm using a 
nanospectrophotometer (Nanodrop ND-1000, Nanodrop 
technologies, Inc. Wilmington, DE USA).
Malondialdehyde assay
Malondialdehyde (MDA) levels were analyzed by 
using thiobarbituric acid reactive substance (TBARS) 
assay with minor modifications [90]. This method is 
based on the reaction of MDA, a breakdown product 
of lipid peroxides, with TBA. To evaluate the basal 
concentration of MDA, 50 μg of total protein dissolved 
in 300 μl of milliQ water were added to 600 μl of TBARS 
solution containing 15% TCA in 0.25 N HCl and 26 mM 
TBA. The mixture was incubated for 40 min. at 100 °C, 
centrifuged at 14,000 rpm for 2 min., and the supernatant 
was analyzed by spectrophotometer at 532 nm. Different 
MDA concentrations (0.75, 1, and 2 μM) were used to 
obtain a standard curve.
Data analysis
Results were expressed as mean ± SEM from at least 
three independent experiments. The statistical significance 
of parametric differences among the sets of experimental 
data was evaluated by one-way ANOVA and Dunnett’s test 
for multiple comparisons.
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